欧普康视：取得滴眼剂药品生产许可证

Core Viewpoint - The company, Opcon Vision (300595), has recently received a Drug Production License for eye drops from the Anhui Provincial Drug Administration, marking its first acquisition of such a license [1] Group 1: License Acquisition - The Drug Production License is a significant regulatory milestone for the company, allowing it to proceed with further necessary regulatory steps for commercialization [1] - The company must still complete product registration applications, on-site inspections, and compliance checks with Good Manufacturing Practices (GMP) before obtaining the Drug Registration Certificate [1] Group 2: Impact on Business - The acquisition of the Drug Production License is not expected to have a significant short-term impact on the company's operating performance [1]